Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo

International Journal of Oncology

Volumn 35, Issue 3, 2009, Pages 583-591

  Fu, Yanchao ^a   Zhang, Qingyu ^a   Kang, Chunsheng ^a   Zhang, Kairu ^a   Zhang, Jing ^a   Pu, Peiyu ^a   Wang, Guangxiu ^a   Wang, Tao ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Gene therapy; Invasion; Malignant tumor; Proliferation; RNA interference

Indexed keywords

ADENOVIRUS VECTOR; AKT1 PROTEIN; CYCLIN D1; CYCLINE; CYCLOOXYGENASE 2; GELATINASE A; GELATINASE B; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE REGULATORY SUBUNIT 1; PROTEIN KINASE B; PROTEIN P53; SHORT HAIRPIN RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL INVASION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE TARGETING; GLIOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; STOMACH ADENOCARCINOMA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOVIRIDAE; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; DOWN-REGULATION; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASMS, EXPERIMENTAL; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349108437     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000369     Document Type: Article

References (41)

1. Khalighinejad N, Hariri H, Behnamfar O, Yousefi A and Momeni A: Amir Momeni Adenoviral gene therapy in gastric cancer. World J Gastroenterol 14: 180-184, 2008.
2. Yonemura Y, Wu CC, Fukushima N, Honda I, Bandou E and Kawamura T: Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. Int J Clin Oncol 13: 132-137, 2008.
3. Tajima Y, Yamazaki K, Makino R, Nishino N, Aoki S and Kato M: Gastric and intestinal phenotypic marker expression in early differentiated-type tumors of the stomach: clinicopathologic significance and genetic background. Clin Cancer Res 12: 6469-6479, 2006.
4. Bernstein E, Caudy AA, Hammond SM and Hannon GJ: Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409: 363-366, 2001.
5. Hammond SM, Bernstein E, Beach D and Hannon GJ: An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404: 293-296, 2000.
6. Bernstein E, Denli AM and Hannon GJ: The rest is silence. RNA 7: 1509-1521, 2001.
7. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE and Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811, 1998.
8. Zamore PD: RNA interference: listening to the sound of silence. Nat Struct Biol 8: 746-751, 2001.
9. Sijen T, Fleenor J, Simmer F, Thijssen KL, Parrish S and Timmons L: On the role of RNA amplification in dsRNA-triggered gene silencing. Cell 107: 465-476, 2001.
10. Ristimaki A, Sivula A, Lundin M, et al: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62: 632-635, 2002.
11. Harris RE, Chlebowski RT, Jackson RD, et al: Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 63: 6096-6101, 2003.
12. Lala PK, Parhar RS and Singh P: Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumor-bearing mice and prevents tumor metastasis. Cell Immunol 99: 108-118, 1986.
13. Masferrer JL, Leahy KM, Koki AT, et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60: 1306-1311, 2000.
14. Kundu N and Fulton AM: Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 62: 2343-2346, 2002.
15. Sheng H, Shao J, Morrow JD, Beauchamp RD and DuBois RN: Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58: 362-366, 1998.
16. Narumiya S, Sugimoto Y and Ushikubi F: Prostanoid receptors: structures properties and functions. Physiol Rev 79: 1193-1226, 1999.
17. Fujino H and Regan JW: Prostanoid receptors and phosphatidyl 3-kinase: a pathway to cancer? Trends Pharmacol Sci 24: 335-340, 2003.
18. Namba T, Sugimoto Y, Negishi M, et al: Alternative splicing of c-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature 365: 166-170, 1993.
19. Cully M, You H, Levine AJ and Mak TW: Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6: 184-192, 2006.
20. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
21. Fingar DC and Blenis J: Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171, 2004.
22. Duan C, Bauchat JR and Hsieh T: Phosphatidylinositol 3-kinase is required for insulin-like growth factor-I-induced vascular smooth muscle cell proliferation and migration. Circ Res 86: 15-23, 2000.
23. Cartwright JE, Tse WK and Whitley GS: Hepatocyte growth factor induced human trophoblast motility involves phosphatidylinositol-3-kinase, mitogen-activated protein kinase, and inducible nitric oxide synthase. Exp Cell Res 279: 219-226, 2002.
24. Qiu Q, Yang M, Tsang BK and Gruslin A: EGF-induced trophoblast secretion of MMP-9 and TIMP-1 involves activation of both PI3K and MAPK signalling pathways. Reproduction 128: 355-363, 2004.
25. Grimm D and Kay MA: Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest 117: 3633-3641, 2007.
26. Almeida R and Allshire RC: RNA silencing and genome regulation. Trends Cell Biol 15: 251-258, 2005.
27. Zhang H, Kolb FA, Jaskiewicz L, Westhof E and Filipowicz W: Single processing center models for human Dicer and bacterial RNase III. Cell 118: 57-68, 2004.
28. Aagaard L and Rossi JJ: RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 59: 75-86, 2007.
29. Tang G: siRNA and miRNA: an insight into RISCs. Trends Biochem Sci 30: 106-114, 2005.
30. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N and Zamore PD: Asymmetry in the assembly of the RNAi enzyme complex. Cell 115: 199-208, 2003.
31. Khvorova A, Reynolds A and Jayasena SD: Functional siRNAs and miRNAs exhibit strand bias. Cell 115: 209-216, 2003.
32. Richard CM: The basic science of gene therapy. Science 260: 926-932, 1993.
33. Yang YC, Huang WF, Chuan LM, Xiao DW, Zeng YL and Zhou DA: In vitro and in vivo study of cell growth inhibition of simvastatin on chronic myelogenous leukemia cells. Chemotherapy 54: 438-446, 2008.
34. Oliveira MG, Lauxen Ida S, Chaves AC, Rados PV and Sant'Ana Filho M: Immunohistochemical analysis of the patterns of p53 and PCNA expression in odontogenic cystic lesions. Med Oral Pathol Oral Cir Bucal 13: E275-E280, 2008.
35. Hartwell LH and Kastan MB: Cell cycle control and cancer. Science 266: 1821-1837, 1994.
36. Lebeau A, Unholzer A, Amann G, Kronawitter M, Bauerfeind I and Sendelhofert A: EGFR, HER-2/neu, Cyclin D1, p2l and p53 in correlation to cell proliferation and steroid hormone receptor status in ducta1 carcinoma in situ of the breast. Breast Cancer Res Treat 79: 187-198, 2003.
37. Yamamoto H, Ochiya T, Takeshita F, Toriyama-Baba H, Hirai K and Sasaki H: Enhanced skin carcinogenesis in Cyclin D1-conditional transgenic mice: cyclin Dl alters keratinocyte response to calcium-induced terminal differentiation. Cancer Res 62: 1641-1647, 2002.
38. Mott JD and Werb Z: Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16: 558-564, 2004.
39. Nagase H, Visse R and Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69: 562-573, 2006.
40. Cawston TE and Wilson AJ: Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol 20: 983-1002, 2006.
41. Baker EA, Stephenson TJ, Reed MW and Brown NJ: Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol 55: 300-304, 2002.